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A B S T R A C T
Our aim was to assess malignancy risk in adenomatoid nodules and suspicious follicular lesions of the thyroid ob-
tained by fine needle aspiration (FNA) cytology. Retrospective research was performed of 276 patients who underwent
thyroid surgery after preoperative ultrasound-guided FNA diagnosis of either adenomatoid nodule, cellular follicular
lesion, »suspicious for follicular neoplasm» or follicular neoplasm. Out of 276 patients, FNA reports showed 15 diagno-
ses (5%) of adenomatoid nodules, 73 (26%) cellular follicular lesions, 76 (28%) »suspicious for follicular neoplasm«, and
112 diagnoses (41%) of follicular neoplasm. FNA reports were compared with pathohistological findings. In FNA re-
ports of adenomatoid nodule (N=15), there were seven (47%) pathohistological diagnoses (PHDs) of nodular goiter, and
eight (53%) PHDs of follicular adenoma. In FNA reports of cellular follicular lesion (N=73), there were 2 (3%) PHDs of
thyroiditis, 32 (44%) PHDs of nodular goiter, 38 (52%) PHDs of follicular adenoma, and one (1%) PHD of papillary car-
cinoma. In FNA reports of »suspicious for follicular neoplasm« (N=76), there was one (1%) PHD of thyroiditis, 24 (32%)
PHDs of nodular goiter, 47 (62%) PHDs of follicular adenoma and four (5%) diagnoses of papillary carcinoma. In FNA
reports of follicular neoplasm (N=112), there were 25 (22%) PHDs of nodular goiter, 72 (64%) PHDs of follicular
adenoma, and 15 (14%) PHDs of thyroid carcinoma. We found significant difference (p<0.01) between investigated FNA
report groups according to malignancy risk. Stratification of cytologic diagnoses of follicular thyroid lesions into differ-
ent subcategories with various probabilities of malignancy allows more accurate estimation of malignancy risk and indi-
vidualized patient treatment, when deciding between immediate operation and close follow-ups with repeat FNA.
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Introduction
Fine-needle aspiration (FNA) biopsy has become the
dominant method in the evaluation of thyroid nodules1,
because it is rapid, reliable, safe, minimally invasive and
cost-effective. The results of FNA are used to assess the
need for resection of thyroid nodules, eliminating those
that do not require surgery, thus decreasing the number
of diagnostic surgical procedures2–5. Nevertheless, there
are certain limitations to the method, which results in in-
determinate results for neoplasm in 5–29% of patients
(patients)6. Such patients still need to be operated to
fully evaluate their status on pathohistological diagnosis
(PHD), and are therefore submitted to potential preoper-
ative morbidity, with additional costs to health-care
system.
Management of patients with FNA-diagnosis of fol-
licular lesions of the thyroid is the most controversial,
because the diagnosis of follicular thyroid carcinoma can
be made only histopathologically, by identification of cap-
sular or vascular invasion, extrathyroidal tissue inva-
sion, or nodal or distant metastasis. Cytological findings
in aspirates from adenomatoid nodules, follicular ade-
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nomas, well-differentiated follicular carcinomas, and fo-
llicular variant of papillary carcinomas or papillary carci-
nomas with prominent follicular component are often
very similar and overlapping, with limited possibilities of
accurate cytological diagnosis, causing discrepancies be-
tween FNAs and PHDs, and often resulting in indetermi-
nate FNA diagnoses of follicular lesions of the thyroid7–12.
Our aim was to assess risk of malignancy in ade-
nomatoid nodules and suspicious follicular lesions of the
thyroid obtained by fine needle aspiration cytology.
Patients and Methods
Patients
We undertook a retrospective research of 276 patients
who underwent thyroid surgery at our hospital from
March 1995 until July 2007 and had preoperative ultra-
sound guided FNA diagnosis of adenomatoid nodule, cel-
lular follicular lesion, »suspicious for follicular neoplasm«
or follicular neoplasm, respectively. There were 37 men
and 239 women. The mean age of patients was 48.5±14.1
years (median 51; range 13–79 years).
Methods
Routine percutaneous, ultrasonographycally guided,
FNA was performed by cytopathologist, using a 23-gauge
needle attached to a 10-mL syringe. Aspirated material
was smeared onto glass slides, air-fixed, stained by May-
-Grünwald-Giemsa method, and consecutively examined
with light microscope. Cytomorphological criteria for
each of the above mentioned FNA diagnostic categories
for follicular lesions were strictly followed.
Cytomorphological criteria for adenomatoid nodule
were at least one of these characteristics: many sheets of
follicular cells with few colloid or enlarged follicular cells
or many microfollicles (Figure 1). Differential diagnosis
includes: adenomatoid nodule of nodular goiter and fol-
licular adenoma. Cytomorphological criteria for cellular
follicular lesion were at least one of these characteristics:
few acinar structures with predominance of normal ap-
pearing sheets of follicular cells or slightly atypical nuclei
(Figure 2). Differential diagnosis includes: adenomatoid
nodule of nodular goiter, follicular adenoma and low pos-
sibility of well-differentiated carcinoma. Cellular follicu-
lar lesion is best described as »probably neoplastic«. A
cytomorphological criterion for »suspicious for follicular
neoplasm« was: many acinar structures with predomi-
nance over normal appearing sheets of follicular cells
(Figure 3). Differential diagnosis includes: adenomatoid
nodule of nodular goiter, follicular adenoma and well-dif-
ferentiated carcinoma. Cytomorphological criteria for fol-
licular neoplasm were at least one of these characteris-
tics: acinar structures without presence of normal ap-
pearing sheets of follicular cells or acinar structures with
moderately atypical nuclei (Figure 4). Differential diag-
nosis includes: follicular adenoma, well-differentiated car-
cinoma, and low possibility of adenomatoid nodule of
nodular goiter. Fine-needle aspiration results were sub-
sequently compared with final PHDs, which were used as
»gold standard». Statistical analysis was performed with
Fisher’s exact test. A p value of <0.05 was considered
significant.
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Fig. 1. Fine-needle biopsy smear of adenomatoid nodule –
PHD nodular goiter (May-Grünwald-Giemsa stain, x 200).
Fig. 2. Fine-needle biopsy smear of cellular follicular lesion –
PHD nodular goiter (May-Grünwald-Giemsa stain, x 200).
Fig. 3. Fine-needle biopsy smear of »suspicious for follicular
neoplasm« – PHD follicular adenoma (May-Grünwald-Giemsa
stain, x 200).
Results
Out of 276 patients examined, FNA reports showed
15 diagnoses (5%) of adenomatoid nodules, 73 diagnoses
(26%) of cellular follicular lesions, 76 patients (28%)
were cytologically diagnosed as »suspicious for follicular
neoplasm», and the remaining 112 patients (41%) were
diagnosed as having follicular neoplasm on FNA smears.
FNA reports were compared with pathohistological find-
ings, and the following results were found (Table 1). In
FNA reports of adenomatoid nodule (N=15), PHDs re-
vealed 7 cases (47%) of nodular goiter, and 8 (53%) of
follicular adenoma. In FNA reports of cellular follicular
lesion (N=73), PHDs were in 2 cases (3%) consistent
with thyroiditis, in 32 (44%) with nodular goiter, in 38
(52%) with follicular adenoma, and in one (1%) with pap-
illary carcinoma. In FNA reports of »suspicious for folli-
cular neoplasm» (N=75), according to the subsequent
PHDs, there was one patient (1%) with thyroiditis, 24
(32%) with nodular goiter, 47 (62%) with follicular ade-
noma, and 4 (5%) with papillary carcinoma. In FNA re-
ports of follicular neoplasm (N=112), there were 25
PHDs (22%) of nodular goiter, 72 (64%) of follicular
adenoma, and 15 (14%) of thyroid carcinoma (14 pri-
mary, 1 metastatic renal cell carcinoma). We found
significant difference (Fisher’s exact test, p<0.01) be-
tween investigated FNA report groups according to the
risk of malignancy (Table 2).
Discussion and Conclusion
Follicular lesions have always been the sore point of
thyroid FNA, because its inability to distinguish them re-
liably, due to the inherent limitation of the method,
based on the overlapping cytological criteria of different
types of follicular lesions, both benign and malignant13.
Several decades ago, it was presumed that smears that
are highly cellular with little or no colloid were charac-
teristic of neoplasms, while aspirates from colloid nod-
ules showed abundant colloid and a relative paucity of
follicular cells14,15. However, soon afterwards it was no-
ted by several investigators that smears from nodular
goiters with adenomatous hyperplasia could be cellular
and could lack significant amount of colloid5,16–18, while,
in contrast, others showed the presence of colloid in some
smears from papillary carcinoma19. These findings were
in contradiction with previous postulates that the pres-
ence of a significant amount of colloid ruled out a neo-
plasm. Follicular thyroid lesions account for up to 30% of
all cytologic diagnoses6,20, and present an ongoing chal-
lenge in thyroid cytology21,22.
In our study, out of 276 patients with FNA reports of
adenomatoid nodule, cellular follicular lesion, »suspi-
cious for follicular neoplasm» or follicular neoplasm, 67%
(185 patients) correlated histologically with thyroid neo-
plasm, benign or malignant, while 91 patients (33%) had
non-tumor diseases (either thyroiditis or nodular goiter).
In comparison, 78% of FNA reports of follicular neo-
plasms correlated with neoplasms on subsequent histo-
logical examination. This is in concordance with findings
from other authors12. There were 256 PHD diagnoses of
benign lesions (93%), and 20 PHD diagnoses of malig-
nant lesions (7%). Higher proportion of malignant dis-
eases is often reported by other authors, ranging from
23%–31%5,12,23–26. Others report similar rates of malig-
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Fig. 4. Fine-needle biopsy smear of follicular neoplasm – PHD
follicular adenoma (May-Grünwald-Giemsa stain, x200).
TABLE 1
CORRELATION BETWEEN FINE-NEEDLE ASPIRATION CYTOLOGIC FINDINGS (FNA) AND PATHOHISTOLOGIC DIAGNOSES (PHD)
IN PATIENTS WITH FOLLICULAR LESIONS OF THE THYROID
FNA
PHD
NG HT FA HCA HCC IC META CA FC MC PC Total
Adenomatoid nodule 7 0 8 0 0 0 0 0 0 0 15
Cellular follicular lesion 32 2 38 0 0 0 0 0 0 1 73
»Suspicious for
follicular neoplasm«
24 1 44 3 0 0 0 0 0 4 76
Follicular neoplasm 25 0 68 4 2 1 1 4 2 5 112
Total 88 3 158 7 2 1 1 4 2 10 276
NG – nodular goiter; HT – Hashimoto thyroiditis; FA – follicular adenoma; HCA – Hürthle cell adenoma; HCC – Hürthle cell carci-
noma; IC – insular carcinoma; META CA –metastatic carcinoma; FC – follicular carcinoma; MC –medullary carcinoma; PC – papillary
carcinoma.
nancies as in our study (10.8%–12%)3,21. One must keep
in mind that different authors often use different cyto-
logic terminology and subclassifications. Different terms
are used to convey the same meaning, while the same
term could have varied significances in different publica-
tions. Authors often do not include the reports of ade-
nomatoid nodule, or even cellular follicular lesion in
their analyses, two cytologic diagnoses that carry very
little, if any, risk of malignant thyroid carcinoma. Differ-
ent reporting schemes are used (two- to six or more cate-
gory schemes) in an attempt to find the best way to esti-
mate the probability of risk of malignancy, and act accor-
dingly27. The other explanation for these differences in
the distribution of malignant vs. benign entities may be
due to different prevalence of them in various patient
populations.
The true incidence of follicular carcinoma is in fact,
currently unknown. Historically, it has been estimated to
account for 10% to 20% of all thyroid cancers, but clinical
practice as well as statistical data in many countries sug-
gests that these figures are no longer accurate28,29. Folli-
cular carcinoma has been associated with iodine defi-
ciency, which has been successfully eliminated in many
countries due to iodine prophylaxis via iodine supple-
mentation in food products. Eradication of iodine defi-
ciency disorders corresponded with decreasing absolute
incidence of follicular carcinoma28–30. Lower relative inci-
dence of follicular carcinoma in recent decades partly co-
mes as a result of changing pathohistological criteria31,
and partly because of a relative increase in the incidence
of papillary carcinoma, as a result of improved diagnostic
techniques and more frequent32 (often excessive and un-
necessary) use of ultrasound. It seems that nowadays the
prevalence of follicular thyroid cancer is truly less than
10%, according to some reports even less that 5%14,29 and
on the decline, thus decreasing the probability that a
»follicular neoplasm« on FNA report will eventually pro-
ve to be a follicular cancer on PHD33. Considering the
continuing decline in the incidence of follicular thyroid
carcinoma, it is comprehensible that in our study, out of
the 20 patients with histologically confirmed thyroid car-
cinoma, half of them i.e. 10 patients had PHDs of papil-
lary carcinoma, originally reported as cellular follicular
lesion (one out of 73), »suspicious for follicular neo-
plasm» (4 out of 76), and follicular neoplasm (5 out of
112).
Explanations for these occasional cytologic misclas-
sifications of papillary thyroid carcinoma, or more often,
follicular variant of papillary thyroid carcinoma, lies in
the fact that there are cytologic overlapping in the diag-
nostic criteria with these two entities and follicular neo-
plasm or even an adenomatoid nodule. For example,
smears of the follicular variant of papillary carcinoma
may display syncytial-type tissue fragments with a fol-
licular pattern instead of characteristic features such as
monolayer sheets of uniform follicular cells with nuclear
grooves and intranuclear inclusions19,34,35. Thus, FNA,
by itself, is limited in predicting the specific histological
type of neoplasm. In patients with FNAs of follicular neo-
plasm (N=112), out of 15 with PHDs of thyroid carci-
noma, besides 5 with the above mentioned papillary car-
cinoma, 4 had PHDs of follicular carcinoma, while others
had Hürthle cell carcinoma (N=2), medullary carcinoma
(N=2), poorly differentiated (insular) carcinoma (N=1),
and metastatic renal adenocarcinoma (N=1). Reasons for
these discrepancies between cytologic and histological di-
agnoses often lie in cytologic limitations. For instance,
Hürthle cell lesions/neoplasms are in some schemes in-
cluded with follicular lesions as their variant, but some-
times described as a separate entity36,37. In contrast to
the follicular cells of follicular neoplasms, in Hürthle cell
neoplasms, dyshesion of the Hürthle cells could be a use-
ful diagnostic criterion38, but it is not always present in
smears. Medullary thyroid carcinoma may be difficult to
differentiate cytologically from certain follicular lesions
when Hürthle-like cells are present39. Therefore, immu-
nocytochemical and ultrastructural studies should be
performed in dubious cases40. In our two cases of me-
dullary carcinoma misinterpreted as follicular neoplasm
on FNA, smears contained numerous monolayers of round
to oval cells with moderate degree of pleomorphism,
moderate to abundant cytoplasm, and slightly enlarged
round nuclei. The case of insular carcinoma was histo-
logically verified seven yrs after initial cytological diag-
nosis; therefore dedifferentiation of the primary, well-dif-
ferentiated tumor probably occurred.
Thyroid is a frequent site of hematological spread of
the kidney, breast, lung and gastrointestinal carcinomas,
and melanoma41–43. Differentiation between primary thy-
roid tumor and metastatic one is especially challenging
when no medical history of previous malignancy is pres-
ent, even though diagnosis is often difficult to obtain
N. Dabeli} et al.: Malignancy Risk in Thyroid FNA, Coll. Antropol. 34 (2010) 2: 349–354
352
TABLE 2
RISK OF MALIGNANCY ACCORDING TO THE FINE-NEEDLE ASPIRATION CYTOLOGIC FINDINGS OF DIFFERENT SUBCATEGORIES OF
FOLLICULAR LESIONS OF THE THYROID
FNA
PHD
Nodular goiter/Hashimoto thyroiditis (%) Adenoma (%) Carcinoma (%)
Adenomatoid nodule 47 53 0
Cellular follicular lesion 47 52 1
»Suspicious for follicular neoplasm« 33 62 5
Follicular neoplas 22 64 14
even in patients with known primary tumor of non-thy-
roid origin, if the new thyroid nodule emerges. Me-
tastases to the thyroid from renal cell carcinomas are
sometimes especially difficult to diagnose, because cells
contain intranuclear inclusions that mimic primary thy-
roid neoplasm44,45. Immunocytochemistry is the most
helpful adjunct in the evaluation of thyroid nodules in
patients with medical history of malignancy46. In our
case of cytologically unrecognized metastatic renal cell
carcinoma (FNA resembled follicular neoplasm), the as-
pirate showed clusters and single round cells with me-
dium-sized nuclei and abundant, wispy cytoplasm in pa-
tient with no previous medical history of renal carci-
noma. Fortunately, misinterpreted cytologic reports, when
it comes to the type of malignant neoplasm, do not alter
the therapeutic approach; total thyroidectomy (usually
with ex tempore histological analysis on frozen section,
with immediate total thyroidectomy in clear cases of ma-
lignancy) is the generally accepted patient management1.
The important message that evolves from the results
of our study, however, is that different subcategories of
follicular lesions on FNA findings have significantly dif-
fering likelihood of being malignant (Table 2). Thus, out
of 15 FNA diagnoses of adenomatoid nodule, on histo-
logical reports there were no patients with carcinoma,
and the ratio between benign follicular diagnosis (i.e.
adenoma) and non-tumor thyroid disease was practically
the same (1.1:1). Out of 73 patients diagnosed on FNA as
having cellular follicular lesion, only one (1%) had his-
tologically confirmed thyroid carcinoma, while 38 (52%)
had PHD of follicular adenoma, and the remaining 34
(47%) had non-tumor thyroid diseases. Out of 76 patients
diagnosed on FNA as having lesions »suspicious for fol-
licular neoplasm», four of them (5%) had histological di-
agnoses of thyroid carcinoma, 47 (62%) had follicular
adenoma, and 25 (33%) had non-tumor thyroid disor-
ders. Finally, out of 112 patients cytologically diagnosed
as having follicular tumor, there were 15 (14%) histo-
logically confirmed diagnoses of thyroid carcinoma, 72
(64%) PHDs of follicular adenoma, and 25 (22%) of non-
-tumor diseases. Statistical analysis revealed significant
(p<0.01) difference between investigated FNA report
groups according to the risk of malignancy. Despite diffi-
culties encountered in the diagnosis of follicular lesions
of the thyroid, FNA remains valuable and widely ac-
cepted primary screening tool used to assess the need for
resection of thyroid nodules22,47. Taking into account de-
creasing incidence of follicular thyroid carcinoma, inde-
terminate follicular lesions on FNA reports often un-
dergo surgical excision to be ultimately determined as
benign diseases histopathologically48. It is estimated that
70% to 84% of thyroid lesions showing follicular cytology
on FNAs, are ultimately found to be benign on
PHDs6,26,49.
Management of thyroid nodules is based on statistical
data correlating a specific cytologic reading with the
probability of malignancy50. Accordingly, stratification of
cytologic diagnoses into different subcategories with var-
ious probabilities of malignancy allows more accurate as-
sessment of the risk of malignancy51,52. In our study, only
7% of patients overall had malignant tumors. Risk of ma-
lignancy with FNA of adenomatoid nodule was in our se-
ries 0%. Standard procedure in our institution for this di-
agnosis is follow-up with FNA repeated after one year.
Risks of malignancy for cytologic diagnoses of cellular
follicular lesion, »suspicious for follicular neoplasm«, and
follicular neoplasm, were 1%, 5%, and 14%, respectively.
In conclusion, we suggest conservative management53
of patients with cytologic diagnoses of cellular follicular
lesion and »suspicious for follicular neoplasm«, especially
when associated with low risk features, such as negative
tumor markers54 and without suspicious clinical chara-
cteristics55,56. Patients with cytologic diagnosis of fol-
licular neoplasm should undergo surgical treatment57.
Following this approach, positive repercussions on pa-
tients are in minimizing diagnostic, non-therapeutic sur-
gical procedures, with all the negative implications that
surgery carries along.
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PROCJENA RIZIKA OD MALIGNOSTI U ADENOMATOIDNIH ^VOROVA I SUSPEKTNIH
FOLIKULARNIH PROMJENA [TITNJA^E DOBIVENIH CITOLO[KOM PUNKCIJOM
S A @ E T A K
Cilj istra`ivanja bio je procijeniti rizik od malignosti u adenomatoidnih ~vorova i suspektnih folikularnih promjena
{titnja~e dobivenih citolo{kom punkcijom. U~injena je retrospektivna analiza 276 bolesnika kojima je provedena ope-
racija {titnja~e nakon predoperacijske citolo{ke punkcije pod kontrolom ultrazvuka i citolo{ke dijagnoze bilo adeno-
matoidnog ~vora, celularne folikularne promjene, »suspektnog folikularnog tumora« ili folikularnog tumora. Od 276
bolesnika, nalazi citolo{ke punkcije ukazali su na 15 dijagnoza (5%) adenomatoidnih ~vorova, 73 (26%) celularnih foli-
kularnih promjena, 76 (28%) »suspektnih folikularnih tumora« i 112 (41%) folikularnih tumora. Citolo{ke dijagnoze
uspore|ivane su s patohistolo{kim dijagnozama (PHD). Kod citolo{ke dijagnoze adenomatoidnog ~vora (N=15), PHD je
u 7 slu~ajeva (47%) ukazao na nodularnu strumu, a u 8 (53%) na folikularni adenom. Kod citolo{ke dijagnoze celularne
folikularne promjene (N=73), PHD je u 2 slu~aja (3%) ukazao na tireoiditis, u 32 (44%) na nodularnu strumu, u 38
slu~ajeva (52%) na folikularni adenom, te u 1 bolesnika (1%) na papilarni karcinom. U slu~aju citolo{ke dijagnoze
»suspektnog folikularnog tumora« (N=76), PHD je u 1 slu~aju (1%) ukazao na tireoiditis, u 24 slu~aja (32%) na no-
dularnu strumu, u 47 bolesnika (62%) na folikularni adenom i u 4 bolesnika (5%) na papilarni karcinom. Kod citolo{ke
dijagnoze folikularnog tumora (N=112), PHD je u 25 slu~ajeva (22%) odgovarao nodularnoj strumi, u 72 slu~aja (64%)
folikularnom adenomu, te u 15 bolesnika (14%) karcinomu {titnja~e. Utvr|ena je zna~ajna razlika (p<0,01) izme|u
ispitivanih skupina citolo{kih dijagnoza u odnosu na rizik od malignosti. Raspodjela citolo{kih dijagnoza folikularnih
promjena {titnja~e u podskupine s razli~itom vjerojatno{}u malignosti omogu}uje to~niju procjenu rizika od malignosti
i individualizirani pristup lije~enju, kada je potrebno odlu~iti treba li bolesnika odmah uputiti na operaciju ili pre-
poru~iti ~este kontrole s ponavljanjem citolo{ke punkcije.
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